Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; biologics and small molecules both in the nature of pharmaceutical preparations for the treatment of genetically-related inner ear diseases and conditions causing hearing loss; gene therapy products to restore, improve and preserve hearing, namely, genetically engineered tissues for inner ear transplant purposes and drug delivery agents for use in the inner ear consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; gene therapy products, namely, biological preparations for the treatment of inner ear disorders and conditions; viral vectors, non-viral vectors and gene therapy vectors all for medical purposes, namely, therapeutic agents for delivering nucleic acid and other genetic material to nuclei of targeted cells in the human body, for use in gene therapy to treat inner ear disorders and conditions; biotechnological platform technology for gene delivery to biological cells, namely, biological nanoparticles and adenoviruses featuring adeno-associated viral (AAV) vectors therein to provide platforms for specific expressions of biologics with therapeutic effects in gene therapy, all to restore, improve and preserve hearing; biotechnological platform technology for gene delivery to biological cells, namely, biological nanoparticles and adenoviruses featuring adeno-associated viral (AAV) vectors therein to provide platforms for specific expressions of biologics with therapeutic effects in gene therapy, all to treat inner ear disorders and conditions